Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PNP | P00491 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyadenosine SCHEMBL532825 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL193181 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222478 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL593935 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222447 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5982298 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL23982174 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19506291 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL21637036 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19877 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509716-B2 | Functional ligands to target vitamin C | Base Pair Biotechnologies, Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12338434-B1 | Methods and materials for discovery of functional ligands to molecular complexes | Base Pair Biotechnologies, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| US-11970785-B2 | Methods and materials for multiplexed collections of functional ligands | Base Pair Biotechnologies, Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240110237-A1 | FUNCTIONAL LIGANDS | BASE PAIR BIOTECHNOLOGIES INC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11725240-B2 | Functional ligands to opioids and opioid derivatives | Base Pair Biotechnologies, Inc. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230111624-A1 | FUNCTIONAL LIGANDS TO TARGET MOLECULES | BASE PAIR BIOTECHNOLOGIES INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11608356-B1 | Functional ligands to colistin | Base Pair Biotechnologies, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| US-11427825-B2 | Functional ligands to drug compounds | Base Pair Biotechnologies, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022165286-A1 | FUNCTIONAL LIGANDS TO PERTUSSIS TOXIN | Base Pair Biotechnologies, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2018091542-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2018022221-A1 | PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE | ASAVI, LLC (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2018-02-01 | — | — | US | disclosed |
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2012-12-06 | — | — | US | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | HIF1A 2249/4885SMN1; SMN2 2345/4885PNP 4/4885 |
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | HCCS, NTPCR, NSUN2 | HIF1A 2261/4885SMN1; SMN2 2872/4885PNP 10/4885 |
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | ENTPD5, MTAP, SLC29A1 | HIF1A 1656/4885SMN1; SMN2 3178/4885PNP 4/4885 |
| US-12509716-B2 | Functional ligands to target vitamin C | PROC, HMOX2, H1-2 | HIF1A 1339/4885SMN1; SMN2 2757/4885PNP 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.